Aug. 18 at 12:02 PM
$ANVS investors new and old should have lots of confidence as the drug is “more promising than any Alzheimer drug on the market or in development” according to a March 2, 2025 public declaration on Stocktwits by the CEO.
The CEO clearly knows what she’s doing in her own mind with a degree of certainty greater than a 100%. Even CFOs are superfluous given her own repeated historic actions on removing CFOs and taking on the role herself!
https://stocktwits.com/ForestFoxes/message/625572410
She’s a superior CEO who has often stated on the record that she is 900% certain her drug works. That’s why she’s willing to hold a Patient’s Live Forum and tells patients and their families to “Buy stock! It’s the ONLY way out!”.
Other investors in biotech companies in the same space such as
$CGTX $AVXL $SAVA and
$BIVI must comparatively ask themselves:
Is my CEO this committed to creating shareholder value and bringing a drug to Market at this level of confidence and competence?
Why does my CEO bother to have a CFO? Or, any MDs on their staff? Or, accurately share scientific based PRs? Or, bother to listen to their attorneys? Or, accurately compete documents to the SEC when selectively submitted, or …
Does your CEO repeatedly tell you that she’s very good at designing drug trials??
Best 🏆 CEO?
@adamfeuerstein a senior writer and biotech columnist for STAT News, is known for his annual "Best and Worst Biopharma CEO" rankings. He does not have a "CEO of the Year" award himself, but rather, he conducts a poll to determine the best and worst in the biopharma industry. In his 2024 rankings, Remi Barbier of Cassava Sciences was named the "Worst Biopharma CEO". For the "Best Biopharma CEO" category, "The team that developed [Cobenfy] successfully" and the "smartly acquired" Karuna Therapeutics, along with Eli Lilly's David Ricks (who was also the Best Biopharma CEO of 2023), were recognized.
https://www.statnews.com/2024/12/18/worst-biopharma-ceo-2024-remi-barbier-cassava-sciences/#:~:text=Remi%20Barbier%2C%20the%20former%20CEO,had%20a%20very%20bad%20year&text=Adam%20Feuerstein%20is%20a%20senior,doing%20annually%20for%2017%20years.&text=Barbier%20had%20a%20bad%20year,shareholder%20and%20class%2Daction%20lawsuits.
Annovis Bio investors must be 👉 900%